Home › Compare › IGXT vs ORCC

IGXT vs ORCC: Dividend Comparison 2026

IGXT yields 1176.47% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IGXT wins by $78814195.18M in total portfolio value
10 years
IGXT
IGXT
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full IGXT calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — IGXT vs ORCC

📍 IGXT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIGXTORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IGXT + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IGXT pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IGXT
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, IGXT beats the other by $57,395,146,065,124.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IGXT + ORCC for your $10,000?

IGXT: 50%ORCC: 50%
100% ORCC50/50100% IGXT
Portfolio after 10yr
$39407097.61M
Annual income
$33,761,850,626,544.71/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

IGXT
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-23.8
Piotroski
4/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IGXT buys
0
ORCC buys
0
No recent congressional trades found for IGXT or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIGXTORCC
Forward yield1176.47% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$78814195.20M ✓$21.4K
Annual income after 10y$67,523,701,253,088.38 ✓$1.04
Total dividends collected$77969765.27M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: IGXT vs ORCC ($10,000, DRIP)

YearIGXT PortfolioIGXT Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$128,347$117,647.06$11,190$489.61+$117.2K → IGXT
2$1,548,514$1,411,182.61$12,229$256.01+$1.54M → IGXT
3$17,569,052$15,912,142.01$13,216$130.74+$17.56M → IGXT
4$187,523,354$168,724,468.35$14,207$66.02+$187.51M → IGXT
5$1,883,716,681$1,683,066,692.55$15,234$33.17+$1883.70M → IGXT
6$17,816,329,317$15,800,752,468.33$16,317$16.62+$17816.31M → IGXT
7$158,731,384,105$139,667,911,735.60$17,468$8.32+$158731.37M → IGXT
8$1,332,782,916,056$1,162,940,335,063.89$18,695$4.16+$1332782.90M → IGXT
9$10,551,863,503,163$9,125,785,782,982.70$20,006$2.08+$10551863.48M → IGXT
10$78,814,195,201,473$67,523,701,253,088.38$21,407$1.04+$78814195.18M → IGXT

IGXT vs ORCC: Complete Analysis 2026

IGXT — Stock

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Full IGXT Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this IGXT vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IGXT vs SCHDIGXT vs JEPIIGXT vs OIGXT vs KOIGXT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.